The FDA has accepted the New Drug Application for doravirine/islatravir for adults with virologically-suppressed HIV-1 infection.

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 - Amphista Therapeutics ('the Company” or 'Amphista”), a leader in the discovery of ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

Health and Human Services Secretary Robert F. Kennedy Jr. lambasted federal agencies he accused of being overly influenced by ...

BURLINGTON - MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, confirmed Neoclease as the winner of the 2025 North ...

SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Merck & Co., Inc. (NYSE:MRK) is ...